New Delhi, Sep. 1 (PTI): India’s first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of INR 200-400. Union Minister of Science and Technology Jitendra Singh on Thursday attended an event held to announce the scientific completion of the vaccine. Scientific completion implies that R&D activities pertaining to the vaccine are complete and now the next step of making them available to the public would take place. Speaking at the event, Singh said COVID has raised awareness about preventive healthcare leading to the development of vaccines like the one against cervical cancer. “The schemes like Ayushman Bharat have made us think about preventive healthcare and we can now afford it. The Department of Biotechnology has taken a lead in the matter and are in collaborative mode,” he said. “Scientific efforts at
India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in theaffordable price range of Rs 200-400.
Union Health Minister Mansukh Mandaviya on Thursday chaired a meeting with the key experts and officials in view of an upsurge of Covid-19 cases in some states.
Union Health Minister Mansukh Mandaviya on Thursday chaired a meeting with the key experts and officials in view of an upsurge of Covid-19 cases in some states.The meeting discussed the analysis of trend of Covid cases, daily and active cases, .